Essential Hypertension
📧 Sign up to get email alerts when something new happens for Essential Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-12-08Clinical Trial Update: Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control [Phase 3]
A Phase 3 trial comparing olmesartan with chlorthalidone against Benicar HCT for essential hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-12-08Clinical Trial Update: Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control [Phase 3]
Phase 3 trial evaluating olmesartan with chlorthalidone for essential hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-01-19Clinical Trial Update: Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control [Phase 3]
A Phase 3 trial comparing candesartan with chlorthalidone to losartan with hydrochlorothiazide for essential hypertension has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2017-01-19Clinical Trial Update: Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control [Phase 3]
A Phase 3 trial evaluating a fixed-dose combination of candesartan and chlorthalidone for essential hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-05-24Clinical Trial Update: A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. [Phase 4]
A Phase 4 trial evaluating azilsartan on coronary artery plaque in patients with essential hypertension, stable angina, and dyslipidemia has…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-08-25Clinical Trial Update: Microvascular Function in Primary Aldosteronism
The trial NCT02096939 evaluating microvascular function in primary aldosteronism and essential hypertension has been withdrawn.